AU2003268907A1 - Pyridine derivatives as cb2 receptor modulators - Google Patents

Pyridine derivatives as cb2 receptor modulators Download PDF

Info

Publication number
AU2003268907A1
AU2003268907A1 AU2003268907A AU2003268907A AU2003268907A1 AU 2003268907 A1 AU2003268907 A1 AU 2003268907A1 AU 2003268907 A AU2003268907 A AU 2003268907A AU 2003268907 A AU2003268907 A AU 2003268907A AU 2003268907 A1 AU2003268907 A1 AU 2003268907A1
Authority
AU
Australia
Prior art keywords
alkyl
chloro
nicotinamide
isopropyl
phenylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003268907A
Other languages
English (en)
Inventor
Andrew John Eatherton
Gerard Martin Paul Gibiln
Richard Howard Green
Karamjit Singh Jandu
William Leonard Mitchell
Alan Naylor
Giovanni Palombi
Derek Anthony Rawlings
Brian Peter Slingsby
Andrew Richard Whittington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2003268907A1 publication Critical patent/AU2003268907A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003268907A 2002-09-27 2003-09-25 Pyridine derivatives as cb2 receptor modulators Abandoned AU2003268907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0222493.9A GB0222493D0 (en) 2002-09-27 2002-09-27 Compounds
GB0222493.9 2002-09-27
PCT/EP2003/010930 WO2004029026A1 (en) 2002-09-27 2003-09-25 Pyridine derivatives as cb2 receptor modulators

Publications (1)

Publication Number Publication Date
AU2003268907A1 true AU2003268907A1 (en) 2004-04-19

Family

ID=9944904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003268907A Abandoned AU2003268907A1 (en) 2002-09-27 2003-09-25 Pyridine derivatives as cb2 receptor modulators

Country Status (23)

Country Link
US (1) US20060240048A1 (enExample)
EP (1) EP1565442B1 (enExample)
JP (1) JP2006503845A (enExample)
KR (1) KR20050071514A (enExample)
CN (1) CN1703402A (enExample)
AR (1) AR041395A1 (enExample)
AT (1) ATE378317T1 (enExample)
AU (1) AU2003268907A1 (enExample)
BR (1) BR0314635A (enExample)
CA (1) CA2500231A1 (enExample)
DE (1) DE60317555T2 (enExample)
ES (1) ES2294313T3 (enExample)
GB (1) GB0222493D0 (enExample)
IS (1) IS7809A (enExample)
MA (1) MA27448A1 (enExample)
MX (1) MXPA05003263A (enExample)
NO (1) NO20052028L (enExample)
NZ (1) NZ538943A (enExample)
PL (1) PL375990A1 (enExample)
RU (1) RU2005112752A (enExample)
TW (1) TW200413321A (enExample)
WO (1) WO2004029026A1 (enExample)
ZA (1) ZA200502084B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082191A2 (en) 2002-03-28 2003-10-09 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
GB0402355D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402356D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
GB0402357D0 (en) * 2004-02-03 2004-03-10 Glaxo Group Ltd Novel compounds
SE0401342D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds
SE0401345D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
SE0401343D0 (sv) * 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine N oxide as scaffold
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
EA200800562A1 (ru) * 2005-08-09 2008-06-30 Глаксо Груп Лимитед Производные имидазопиридина в качестве лигандов каннабиноидного рецептора
GB0519760D0 (en) * 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds
CA2643863A1 (en) * 2006-04-07 2007-10-18 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
AU2007304363B2 (en) 2006-10-04 2013-01-17 F. Hoffmann-La Roche Ag Pyrazine-2-carboxamide derivatives as CB2 receptor modulators
WO2008063625A2 (en) * 2006-11-20 2008-05-29 Adolor Corporation Pyridine compounds and methods of their use
MX2009009035A (es) * 2007-02-22 2009-12-14 Hemerus Medical Llc Aparato de alta capacidad para filtracion de fluidos biologicos.
KR20110117146A (ko) * 2009-01-22 2011-10-26 라퀄리아 파마 인코포레이티드 Ｃｂ2 수용체 효능활성이 있는 ｎ-치환 포화 헤테로사이클릭 술폰 화합물
EP2415765A4 (en) 2009-03-30 2012-08-15 Astellas Pharma Inc PYRIMIDINE COMPOUND
CN105693601A (zh) * 2009-08-24 2016-06-22 纽若斯丹公司 神经刺激性哌嗪的合成
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
JP2013048962A (ja) * 2012-12-12 2013-03-14 Hemerus Medical Llc 大容量の体液濾過装置
WO2018055640A1 (en) * 2016-09-22 2018-03-29 Srf Limited Process for the preparation of haloalkyl derivatives of nicotinic acid
SG11202009103WA (en) * 2018-06-27 2020-10-29 Hoffmann La Roche Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
CN112119068A (zh) 2018-06-27 2020-12-22 豪夫迈·罗氏有限公司 作为大麻素受体2的抑制剂的新型氮杂环丁烷-取代的吡啶和吡嗪化合物
CN112638430B (zh) 2018-06-27 2023-05-16 豪夫迈·罗氏有限公司 放射性标记的大麻素受体2配体
WO2020025574A1 (en) 2018-08-03 2020-02-06 Bayer Aktiengesellschaft Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process
EP3666759A1 (en) 2018-12-10 2020-06-17 Bayer Aktiengesellschaft Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5112820A (en) * 1990-03-05 1992-05-12 Sterling Drug Inc. Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands

Also Published As

Publication number Publication date
TW200413321A (en) 2004-08-01
CA2500231A1 (en) 2004-04-08
EP1565442B1 (en) 2007-11-14
ES2294313T3 (es) 2008-04-01
KR20050071514A (ko) 2005-07-07
DE60317555T2 (de) 2008-10-23
NZ538943A (en) 2007-01-26
RU2005112752A (ru) 2006-01-20
JP2006503845A (ja) 2006-02-02
BR0314635A (pt) 2005-08-02
IS7809A (is) 2005-04-19
GB0222493D0 (en) 2002-11-06
PL375990A1 (en) 2005-12-12
DE60317555D1 (de) 2007-12-27
ATE378317T1 (de) 2007-11-15
US20060240048A1 (en) 2006-10-26
WO2004029026A1 (en) 2004-04-08
MA27448A1 (fr) 2005-07-01
NO20052028L (no) 2005-06-03
AR041395A1 (es) 2005-05-18
MXPA05003263A (es) 2005-07-05
CN1703402A (zh) 2005-11-30
ZA200502084B (en) 2006-02-22
EP1565442A1 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
AU2003268907A1 (en) Pyridine derivatives as cb2 receptor modulators
EP1562907B1 (en) Pyridine derivatives as cb2 receptor modulators
EP1539712B1 (en) Pyrimidine derivatives and their use as cb2 modulators
EP1534687B1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- or pyridin-4-ylmethyl)carbamoylpyrimidine derivatives as selective cb2 cannabinoid receptor modulators
US20080280952A1 (en) Pyridine Derivatives as Connabinoid Receptor Modulators
EP1718613B1 (en) Pyridine derivatives and their use as cb2 receptor modulators
EP1928833B1 (en) Novel quinoline compounds capable of binding at the cb2 receptor
WO2005080350A1 (en) Pyrimidine derivatives as cannabinoid receptor modulators
EP1732561A1 (en) Combination of cb2 modulators and pde4 inhibitors for use in medicine
US20090264452A1 (en) 2-(Phenylamino)-Pyrimidin-5-Amides As Cannabinoid 2 Receptors Modulators for the Treatment of Immune or Inflammatory Disorders
AU2006278191A1 (en) Imidazopyridine derivatives as cannabinoid receptor ligands
HK1079193B (en) Pyrimidine derivatives and their use as cb2 modulators
AU2007211954A1 (en) Pyrimidine derivatives and their use as CB2 modulators

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application